Bioconjugates for targeted delivery of therapeutic oligonucleotides

Advanced Drug Delivery Reviews

Volumn 87, Issue , 2015, Pages 81-89

  Ming, Xin ^a   Laing, Brian ^a  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

Author keywords

Antisense; Conjugates; Oligonucleotides; SiRNA; Targeted delivery

Indexed keywords

CELL MEMBRANES; CYTOLOGY; HISTOLOGY; MOLECULES; TISSUE;

ANTISENSE; CARRIER MOLECULES; CELL SURFACE RECEPTORS; CONJUGATES; OLIGONUCLEOTIDE CONJUGATES; SIRNA; TARGETED DELIVERY; THERAPEUTIC POTENTIALS;

OLIGONUCLEOTIDES;

ALBUMIN CONJUGATE; ANTIBODY CONJUGATE; ANTISENSE OLIGONUCLEOTIDE; APTAMER; ARC 520; ASIALOGLYCOPROTEIN RECEPTOR; CELL PENETRATING PEPTIDE; CPG OLIGODEOXYNUCLEOTIDE; DRUG CARRIER; GLYCOCONJUGATE; GLYCOPROTEIN GP 120; HUMAN SERUM ALBUMIN; MIPOMERSEN; N ACETYLGALACTOSAMINE; NANOCONJUGATE; NANOPARTICLE; OLIGONUCLEOTIDE; POLYMER; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROTAMINE; SMALL INTERFERING RNA; STAT3 PROTEIN; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; LIGAND; PROTEIN BINDING;

AMYLOIDOSIS; CONJUGATION; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG TARGETING; ENDOCYTOSIS; ENDOSOME; GENE SILENCING; GLOMERULUS FILTRATION; HEMOPHILIA; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; INTERNALIZATION; KIDNEY CLEARANCE; NONHUMAN; PLASMA HALF LIFE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RNA INTERFERENCE; SINGLE DRUG DOSE; TUMOR XENOGRAFT; ANIMAL; CHEMISTRY; METABOLISM;

ANIMALS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; LIGANDS; NANOCONJUGATES; OLIGONUCLEOTIDES; PROTEIN BINDING; RECEPTORS, CELL SURFACE;

EID: 84937252161     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2015.02.002     Document Type: Review

References (102)

1. Hopkins A.L., Groom C.R. The druggable genome. Nat. Rev. Drug Discov. 2002, 1:727-730.
2. Bennett C.F., Swayze E.E. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu. Rev. Pharmacol. Toxicol. 2010, 50:259-293.
3. Wahlestedt C. Targeting long non-coding RNA to therapeutically upregulate gene expression. Nat. Rev. Drug Discov. 2013, 12:433-446.
4. Kole R., Krainer A.R., Altman S. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat. Rev. Drug Discov. 2012, 11:125-140.
5. Eggleston A.K., Eccleston A., Marte B., Lupp C. Regulatory RNA. Nature 2012, 482:321.
6. Janssen H.L., Reesink H.W., Lawitz E.J., Zeuzem S., Rodriguez-Torres M., Patel K., van der Meer A.J., Patick A.K., Chen A., Zhou Y., Persson R., King B.D., Kauppinen S., Levin A.A., Hodges M.R. Treatment of HCV infection by targeting microRNA. N. Engl. J. Med. 2013, 368:1685-1694.
7. Goemans N.M., Tulinius M., van den Akker J.T., Burm B.E., Ekhart P.F., Heuvelmans N., Holling T., Janson A.A., Platenburg G.J., Sipkens J.A., Sitsen J.M., Aartsma-Rus A., van Ommen G.J., Buyse G., Darin N., Verschuuren J.J., Campion G.V., de Kimpe S.J., van Deutekom J.C. Systemic administration of PRO051 in Duchenne's muscular dystrophy. N. Engl. J. Med. 2011, 364:1513-1522.
8. Cirak S., Arechavala-Gomeza V., Guglieri M., Feng L., Torelli S., Anthony K., Abbs S., Garralda M.E., Bourke J., Wells D.J., Dickson G., Wood M.J., Wilton S.D., Straub V., Kole R., Shrewsbury S.B., Sewry C., Morgan J.E., Bushby K., Muntoni F. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 2011, 378:595-605.
9. Tse M.T. Regulatory watch: antisense approval provides boost to field. Nat. Rev. Drug Discov. 2013, 12:179.
10. Coelho T., Adams D., Silva A., Lozeron P., Hawkins P.N., Mant T., Perez J., Chiesa J., Warrington S., Tranter E., Munisamy M., Falzone R., Harrop J., Cehelsky J., Bettencourt B.R., Geissler M., Butler J.S., Sehgal A., Meyers R.E., Chen Q., Borland T., Hutabarat R.M., Clausen V.A., Alvarez R., Fitzgerald K., Gamba-Vitalo C., Nochur S.V., Vaishnaw A.K., Sah D.W., Gollob J.A., Suhr O.B. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N. Engl. J. Med. 2013, 369:819-829.
11. Miller T.M., Pestronk A., David W., Rothstein J., Simpson E., Appel S.H., Andres P.L., Mahoney K., Allred P., Alexander K., Ostrow L.W., Schoenfeld D., Macklin E.A., Norris D.A., Manousakis G., Crisp M., Smith R., Bennett C.F., Bishop K.M., Cudkowicz M.E. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 2013, 12:435-442.
12. Juliano R., Bauman J., Kang H., Ming X. Biological barriers to therapy with antisense and siRNA oligonucleotides. Mol. Pharm. 2009, 6:686-695.
13. Ming X. Cellular delivery of siRNA and antisense oligonucleotides via receptor-mediated endocytosis. Expert Opin. Drug Deliv. 2011, 8:435-449.
14. Whitehead K.A., Langer R., Anderson D.G. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 2009, 8:129-138.
15. Maeda H., Nakamura H., Fang J. The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv. Drug Deliv. Rev. 2013, 65:71-79.
16. Davis M.E., Zuckerman J.E., Choi C.H., Seligson D., Tolcher A., Alabi C.A., Yen Y., Heidel J.D., Ribas A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464:1067-1070.
17. Kanasty R., Dorkin J.R., Vegas A., Anderson D. Delivery materials for siRNA therapeutics. Nat. Mater. 2013, 12:967-977.
18. Li J., Huang L. Targeted delivery of RNAi therapeutics for cancer therapy. Nanomedicine (Lond.) 2010, 5:1483-1486.
19. Li J., Wang Y., Zhu Y., Oupicky D. Recent advances in delivery of drug-nucleic acid combinations for cancer treatment. J. Control. Release 2013, 172:589-600.
20. Tamura A., Nagasaki Y. Smart siRNA delivery systems based on polymeric nanoassemblies and nanoparticles. Nanomedicine (Lond.) 2010, 5:1089-1102.
21. Musacchio T., Torchilin V.P. siRNA delivery: from basics to therapeutic applications. Front. Biosci. 2013, 18:58-79.
22. Nguyen J., Szoka F.C. Nucleic acid delivery: the missing pieces of the puzzle?. Acc. Chem. Res. 2012, 45:1153-1162.
23. Juliano R.L., Ming X., Nakagawa O. The chemistry and biology of oligonucleotide conjugates. Acc. Chem. Res. 2012, 45:1067-1076.
24. Turner J.J., Arzumanov A.A., Gait M.J. Synthesis, cellular uptake and HIV-1 Tat-dependent trans-activation inhibition activity of oligonucleotide analogues disulphide-conjugated to cell-penetrating peptides. Nucleic Acids Res. 2005, 33:27-42.
25. Astriab-Fisher A., Sergueev D., Fisher M., Shaw B.R., Juliano R.L. Conjugates of antisense oligonucleotides with the Tat and antennapedia cell-penetrating peptides: effects on cellular uptake, binding to target sequences, and biologic actions. Pharm. Res. 2002, 19:744-754.
26. Alam M.R., Dixit V., Kang H., Li Z.B., Chen X., Trejo J., Fisher M., Juliano R.L. Intracellular delivery of an anionic antisense oligonucleotide via receptor-mediated endocytosis. Nucleic Acids Res. 2008, 36:2764-2776.
27. Czauderna F., Fechtner M., Dames S., Aygun H., Klippel A., Pronk G.J., Giese K., Kaufmann J. Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res. 2003, 31:2705-2716.
28. Winkler J. Oligonucleotide conjugates for therapeutic applications. Ther. Deliv. 2013, 4:791-809.
29. Singh Y., Murat P., Defrancq E. Recent developments in oligonucleotide conjugation. Chem. Soc. Rev. 2010, 39:2054-2070.
30. Ma Y., Kowolik C.M., Swiderski P.M., Kortylewski M., Yu H., Horne D.A., Jove R., Caballero O.L., Simpson A.J., Lee F.T., Pillay V., Scott A.M. Humanized Lewis-Y specific antibody based delivery of STAT3 siRNA. ACS Chem. Biol. 2011, 6:962-970.
31. Ming X., Carver K., Wu L. Albumin-based nanoconjugates for targeted delivery of therapeutic oligonucleotides. Biomaterials 2013, 34:7939-7949.
32. Juliano R.L., Carver K., Cao C., Ming X. Receptors, endocytosis, and trafficking: the biological basis of targeted delivery of antisense and siRNA oligonucleotides. J. Drug Target. 2013, 21:27-43.
33. Alam M.R., Ming X., Fisher M., Lackey J.G., Rajeev K.G., Manoharan M., Juliano R.L. Multivalent cyclic RGD conjugates fort targeted delivery of small interfering RNA. Bioconjug. Chem. 2011, 22:1673-1681.
34. Nair J.K., Willoughby J.L., Chan A., Charisse K., Alam M.R., Wang Q., Hoekstra M., Kandasamy P., Kel'in A.V., Milstein S., Taneja N., O'Shea J., Shaikh S., Zhang L., van der Sluis R.J., Jung M.E., Akinc A., Hutabarat R., Kuchimanchi S., Fitzgerald K., Zimmermann T., van Berkel T.J., Maier M.A., Rajeev K.G., Manoharan M. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J. Am. Chem. Soc. 2014, 136:16958-16961.
35. Stockert R.J. The asialoglycoprotein receptor: relationships between structure, function, and expression. Physiol. Rev. 1995, 75:591-609.
36. Zhu L., Mahato R.I. Targeted delivery of siRNA to hepatocytes and hepatic stellate cells by bioconjugation. Bioconjug. Chem. 2010, 21:2119-2127.
37. Lorenz C., Hadwiger P., John M., Vornlocher H.P., Unverzagt C. Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg. Med. Chem. Lett. 2004, 14:4975-4977.
38. Soutschek J., Akinc A., Bramlage B., Charisse K., Constien R., Donoghue M., Elbashir S., Geick A., Hadwiger P., Harborth J., John M., Kesavan V., Lavine G., Pandey R.K., Racie T., Rajeev K.G., Rohl I., Toudjarska I., Wang G., Wuschko S., Bumcrot D., Koteliansky V., Limmer S., Manoharan M., Vornlocher H.P. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004, 432:173-178.
39. Wolfrum C., Shi S., Jayaprakash K.N., Jayaraman M., Wang G., Pandey R.K., Rajeev K.G., Nakayama T., Charrise K., Ndungo E.M., Zimmermann T., Koteliansky V., Manoharan M., Stoffel M. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat. Biotechnol. 2007, 25:1149-1157.
40. Nishina K., Unno T., Uno Y., Kubodera T., Kanouchi T., Mizusawa H., Yokota T. Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol. Mol. Ther. 2008, 16:734-740.
41. Petrova N.S., Chernikov I.V., Meschaninova M.I., Dovydenko I.S., Venyaminova A.G., Zenkova M.A., Vlassov V.V., Chernolovskaya E.L. Carrier-free cellular uptake and the gene-silencing activity of the lipophilic siRNAs is strongly affected by the length of the linker between siRNA and lipophilic group. Nucleic Acids Res. 2012, 40:2330-2344.
42. Nakagawa O., Ming X., Huang L., Juliano R.L. Targeted intracellular delivery of antisense oligonucleotides via conjugation with small-molecule ligands. J. Am. Chem. Soc. 2010, 132:8848-8849.
43. Dohmen C., Frohlich T., Lachelt U., Rohl I., Vornlocher H.P., Hadwiger P., Wagner E. Defined folate-PEG-siRNA conjugates for receptor-specific gene silencing. Mol. Ther. Nucleic Acids 2012, 1:e7.
44. Willibald J., Harder J., Sparrer K., Conzelmann K.K., Carell T. Click-modified anandamide siRNA enables delivery and gene silencing in neuronal and immune cells. J. Am. Chem. Soc. 2012, 134:12330-12333.
45. Lindgren M., Langel U. Classes and prediction of cell-penetrating peptides. Methods Mol. Biol. 2011, 683:3-19.
46. van den Berg A., Dowdy S.F. Protein transduction domain delivery of therapeutic macromolecules. Curr. Opin. Biotechnol. 2011, 22:888-893.
47. Abes R., Moulton H.M., Clair P., Yang S.T., Abes S., Melikov K., Prevot P., Youngblood D.S., Iversen P.L., Chernomordik L.V., Lebleu B. Delivery of steric block morpholino oligomers by (R-X-R)4 peptides: structure-activity studies. Nucleic Acids Res. 2008, 36:6343-6354.
48. Ivanova G.D., Arzumanov A., Abes R., Yin H., Wood M.J., Lebleu B., Gait M.J. Improved cell-penetrating peptide-PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle. Nucleic Acids Res. 2008, 36:6418-6428.
49. Yin H., Saleh A.F., Betts C., Camelliti P., Seow Y., Ashraf S., Arzumanov A., Hammond S., Merritt T., Gait M.J., Wood M.J. Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice. Mol. Ther 2011, 19:1295-1303.
50. Saleh A.F., Arzumanov A.A., Gait M.J. Overview of alternative oligonucleotide chemistries for exon skipping. Methods Mol. Biol. 2012, 867:365-378.
51. Alam M.R., Ming X., Dixit V., Fisher M., Chen X., Juliano R.L. The biological effect of an antisense oligonucleotide depends on its route of endocytosis and trafficking. Oligonucleotides 2010, 20:103-109.
52. Liu X., Wang W., Samarsky D., Liu L., Xu Q., Zhang W., Zhu G., Wu P., Zuo X., Deng H., Zhang J., Wu Z., Chen X., Zhao L., Qiu Z., Zhang Z., Zeng Q., Yang W., Zhang B., Ji A. Tumor-targeted in vivo gene silencing via systemic delivery of cRGD-conjugated siRNA. Nucleic Acids Res. 2014, 42:11805-11817.
53. Ming X., Alam M.R., Fisher M., Yan Y., Chen X., Juliano R.L. Intracellular delivery of an antisense oligonucleotide via endocytosis of a G protein-coupled receptor. Nucleic Acids Res. 2010, 38:6567-6576.
54. Basu S., Wickstrom E. Synthesis and characterization of a peptide nucleic acid conjugated to a D-peptide analog of insulin-like growth factor 1 for increased cellular uptake. Bioconjug. Chem. 1997, 8:481-488.
55. Cesarone G., Edupuganti O.P., Chen C.P., Wickstrom E. Insulin receptor substrate 1 knockdown in human MCF7 ER+ breast cancer cells by nuclease-resistant IRS1 siRNA conjugated to a disulfide-bridged D-peptide analogue of insulin-like growth factor 1. Bioconjug. Chem. 2007, 18:1831-1840.
56. Yin H., Moulton H.M., Betts C., Seow Y., Boutilier J., Iverson P.L., Wood M.J. A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice. Hum. Mol. Genet. 2009, 18:4405-4414.
57. Nakagawa O., Ming X., Carver K., Juliano R. Conjugation with receptor-targeted histidine-rich peptides enhances the pharmacological effectiveness of antisense oligonucleotides. Bioconjug. Chem. 2014, 25:165-170.
58. Sievers E.L., Senter P.D. Antibody-drug conjugates in cancer therapy. Annu. Rev. Med. 2013, 64:15-29.
59. Schneider B., Grote M., John M., Haas A., Bramlage B., Ickenstein L.M., Jahn-Hofmann K., Bauss F., Cheng W., Croasdale R., Daub K., Dill S., Hoffmann E., Lau W., Burtscher H., Ludtke J.L., Metz S., Mundigl O., Neal Z.C., Scheuer W., Stracke J., Herweijer H., Brinkmann U. Targeted siRNA delivery and mRNA knockdown mediated by bispecific digoxigenin-binding antibodies. Mol. Ther. Nucleic Acids 2012, 1:e46.
60. Gold L., Janjic N., Jarvis T., Schneider D., Walker J.J., Wilcox S.K., Zichi D. Aptamers and the RNA world, past and present. Cold Spring Harb. Perspect. Biol. 2012, 4.
61. Tan W., Wang H., Chen Y., Zhang X., Zhu H., Yang C., Yang R., Liu C. Molecular aptamers for drug delivery. Trends Biotechnol. 2011, 29:634-640.
62. Keefe A.D., Pai S., Ellington A. Aptamers as therapeutics. Nat. Rev. Drug Discov. 2010, 9:537-550.
63. Chu T.C., Twu K.Y., Ellington A.D., Levy M. Aptamer mediated siRNA delivery. Nucleic Acids Res. 2006, 34:e73.
64. McNamara J.O., Andrechek E.R., Wang Y., Viles K.D., Rempel R.E., Gilboa E., Sullenger B.A., Giangrande P.H. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat. Biotechnol. 2006, 24:1005-1015.
65. Dassie J.P., Liu X.Y., Thomas G.S., Whitaker R.M., Thiel K.W., Stockdale K.R., Meyerholz D.K., McCaffrey A.P., McNamara J.O., Giangrande P.H. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat. Biotechnol. 2009, 27:839-849.
66. Zhou J., Swiderski P., Li H., Zhang J., Neff C.P., Akkina R., Rossi J.J. Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res. 2009, 37:3094-3109.
67. Zhou J., Li H., Li S., Zaia J., Rossi J.J. Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol. Ther. 2008, 16:1481-1489.
68. Kortylewski M., Swiderski P., Herrmann A., Wang L., Kowolik C., Kujawski M., Lee H., Scuto A., Liu Y., Yang C., Deng J., Soifer H.S., Raubitschek A., Forman S., Rossi J.J., Pardoll D.M., Jove R., Yu H. In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat. Biotechnol. 2009, 27:925-932.
69. Nechaev S., Gao C., Moreira D., Swiderski P., Jozwiak A., Kowolik C.M., Zhou J., Armstrong B., Raubitschek A., Rossi J.J., Kortylewski M. Intracellular processing of immunostimulatory CpG-siRNA: Toll-like receptor 9 facilitates siRNA dicing and endosomal escape. J. Control. Release 2013, 170:307-315.
70. Rozema D.B., Lewis D.L., Wakefield D.H., Wong S.C., Klein J.J., Roesch P.L., Bertin S.L., Reppen T.W., Chu Q., Blokhin A.V., Hagstrom J.E., Wolff J.A. Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:12982-12987.
71. Parmar R.G., Poslusney M., Busuek M., Williams J.M., Garbaccio R., Leander K., Walsh E., Howell B., Sepp-Lorenzino L., Riley S., Patel M., Kemp E., Latham A., Leone A., Soli E., Burke R.S., Carr B., Colletti S.L., Wang W. Novel endosomolytic poly(amido amine) polymer conjugates for systemic delivery of siRNA to hepatocytes in rodents and nonhuman primates. Bioconjug. Chem. 2014, 25:896-906.
72. Guidry E.N., Farand J., Soheili A., Parish C.A., Kevin N.J., Pipik B., Calati K.B., Ikemoto N., Waldman J.H., Latham A.H., Howell B.J., Leone A., Garbaccio R.M., Barrett S.E., Parmar R.G., Truong Q.T., Mao B., Davies I.W., Colletti S.L., Sepp-Lorenzino L. Improving the in vivo therapeutic index of siRNA polymer conjugates through increasing pH responsiveness. Bioconjug. Chem. 2014, 25:296-307.
73. Parmar R.G., Busuek M., Walsh E.S., Leander K.R., Howell B.J., Sepp-Lorenzino L., Kemp E., Crocker L.S., Leone A., Kochansky C.J., Carr B.A., Garbaccio R.M., Colletti S.L., Wang W. Endosomolytic bioreducible poly(amido amine disulfide) polymer conjugates for the in vivo systemic delivery of siRNA therapeutics. Bioconjug. Chem. 2013, 24:640-647.
74. Wong S.C., Klein J.J., Hamilton H.L., Chu Q., Frey C.L., Trubetskoy V.S., Hegge J., Wakefield D., Rozema D.B., Lewis D.L. Co-injection of a targeted, reversibly masked endosomolytic polymer dramatically improves the efficacy of cholesterol-conjugated small interfering RNAs in vivo. Nucleic Acid Ther. 2012, 22:380-390.
75. Wooddell C.I., Rozema D.B., Hossbach M., John M., Hamilton H.L., Chu Q., Hegge J.O., Klein J.J., Wakefield D.H., Oropeza C.E., Deckert J., Roehl I., Jahn-Hofmann K., Hadwiger P., Vornlocher H.P., McLachlan A., Lewis D.L. Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection. Mol. Ther. 2013, 21:973-985.
76. Sebestyen M.G., Wong S.C., Trubetskoy V., Lewis D.L., Wooddell C.I. Targeted in vivo delivery of siRNA and an endosome-releasing agent to hepatocytes. Methods Mol. Biol. 2015, 1218:163-186.
77. Elsadek B., Kratz F. Impact of albumin on drug delivery-new applications on the horizon. J. Control. Release 2012, 157:4-28.
78. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J. Control. Release 2008, 132:171-183.
79. Lund U., Rippe A., Venturoli D., Tenstad O., Grubb A., Rippe B. Glomerular filtration rate dependence of sieving of albumin and some neutral proteins in rat kidneys. Am. J. Physiol. Renal Physiol. 2003, 284:F1226-F1234.
80. Kang H., Alam M.R., Dixit V., Fisher M., Juliano R.L. Cellular delivery and biological activity of antisense oligonucleotides conjugated to a targeted protein carrier. Bioconjug. Chem. 2008, 19:2182-2188.
81. Carver K., Ming X., Juliano R.L. Tumor cell-targeted delivery of nanoconjugated oligonucleotides in composite spheroids. Nucleic Acid Ther. 2014, 24:413-419.
82. Carver K., Ming X., Juliano R.L. Multicellular tumor spheroids as a model for assessing delivery of oligonucleotides in three dimensions. Mol. Ther. Nucleic Acids 2014, 3:e153.
83. Ming X., Carver K., Fisher M., Noel R., Cintrat J.C., Gillet D., Barbier J., Cao C., Bauman J., Juliano R.L. The small molecule Retro-1 enhances the pharmacological actions of antisense and splice switching oligonucleotides. Nucleic Acids Res. 2013, 41:3673-3687.
84. Eguchi A., Meade B.R., Chang Y.C., Fredrickson C.T., Willert K., Puri N., Dowdy S.F. Efficient siRNA delivery into primary cells by a peptide transduction domain-dsRNA binding domain fusion protein. Nat. Biotechnol. 2009, 27:567-571.
85. Song E., Zhu P., Lee S.K., Chowdhury D., Kussman S., Dykxhoorn D.M., Feng Y., Palliser D., Weiner D.B., Shankar P., Marasco W.A., Lieberman J. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol. 2005, 23:709-717.
86. Peer D., Zhu P., Carman C.V., Lieberman J., Shimaoka M. Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:4095-4100.
87. Kumar P., Ban H.S., Kim S.S., Wu H., Pearson T., Greiner D.L., Laouar A., Yao J., Haridas V., Habiro K., Yang Y.G., Jeong J.H., Lee K.Y., Kim Y.H., Kim S.W., Peipp M., Fey G.H., Manjunath N., Shultz L.D., Lee S.K., Shankar P. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 2008, 134:577-586.
88. de Vries J.W., Zhang F., Herrmann A. Drug delivery systems based on nucleic acid nanostructures. J. Control. Release 2013, 172:467-483.
89. Pinheiro A.V., Han D., Shih W.M., Yan H. Challenges and opportunities for structural DNA nanotechnology. Nat. Nanotechnol. 2011, 6:763-772.
90. Lo P.K., Metera K.L., Sleiman H.F. Self-assembly of three-dimensional DNA nanostructures and potential biological applications. Curr. Opin. Chem. Biol. 2010, 14:597-607.
91. Lee H., Lytton-Jean A.K.R., Chen Y., Love K.T., Park A.I., Karagiannis E.D., Sehgal A., Querbes W., Zurenko C.S., Jayaraman M., Peng C.G., Charisse K., Borodovsky A., Manoharan M., Donahoe J.S., Truelove J., Nahrendorf M., Langer R., Anderson D.G. Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery. Nat. Nanotechnol. 2012, 7:389-393.
92. Li J., Pei H., Zhu B., Liang L., Wei M., He Y., Chen N., Li D., Huang Q., Fan C. Self-assembled multivalent DNA nanostructures for noninvasive intracellular delivery of immunostimulatory CpG oligonucleotides. ACS Nano 2011, 5:8783-8789.
93. Haque F., Shu D., Shu Y., Shlyakhtenko L.S., Rychahou P.G., Evers B.M., Guo P. Ultrastable synergistic tetravalent RNA nanoparticles for targeting to cancers. Nano Today 2012, 7:245-257.
94. Shu D., Shu Y., Haque F., Abdelmawla S., Guo P. Thermodynamically stable RNA three-way junction for constructing multifunctional nanoparticles for delivery of therapeutics. Nat. Nanotechnol. 2011, 6:658-667.
95. Charoenphol P., Bermudez H. Aptamer-targeted DNA nanostructures for therapeutic delivery. Mol. Pharm. 2014, 11:1721-1725.
96. Zheng D., Giljohann D.A., Chen D.L., Massich M.D., Wang X.Q., Iordanov H., Mirkin C.A., Paller A.S. Topical delivery of siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:11975-11980.
97. Choi C.H., Hao L., Narayan S.P., Auyeung E., Mirkin C.A. Mechanism for the endocytosis of spherical nucleic acid nanoparticle conjugates. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:7625-7630.
98. Patel P.C., Giljohann D.A., Daniel W.L., Zheng D., Prigodich A.E., Mirkin C.A. Scavenger receptors mediate cellular uptake of polyvalent oligonucleotide-functionalized gold nanoparticles. Bioconjug. Chem. 2010, 21:2250-2256.
99. Zhang K., Hao L., Hurst S.J., Mirkin C.A. Antibody-linked spherical nucleic acids for cellular targeting. J. Am. Chem. Soc. 2012, 134:16488-16491.
100. Vigderman L., Zubarev E.R. Therapeutic platforms based on gold nanoparticles and their covalent conjugates with drug molecules. Adv. Drug Deliv. Rev. 2013, 65:663-676.
101. Lu W., Zhang G., Zhang R., Flores L.G., Huang Q., Gelovani J.G., Li C. Tumor site-specific silencing of NF-kappaB p65 by targeted hollow gold nanosphere-mediated photothermal transfection. Cancer Res. 2010, 70:3177-3188.
102. Maier M. Advances in systemic delivery of RNAi therapeutics. 12th US-Japan Symposium on Drug Delivery Systems, Lahaina, Maui, Hawaii, USA 2013.